Priority review for Genentech’s eye drug Lucentis
US regulators are undertaking a speedy review of Genentech’s eye drug Lucentis for the treatment of myopic choroidal neovascularisation (mCNV), a complication of severe near-sightedness that can lead to blindness.
Read More
